NCT04366232 (JAKINCOV) is a Phase 2 clinical trial of Anakinra alone (stages 2b/3) in Covid-19, sponsored by Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer.

Who is sponsoring NCT04366232?

NCT04366232 is sponsored by Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer.

What drugs are being tested in NCT04366232?

Interventions in NCT04366232: Anakinra alone (stages 2b/3), Anakinra and Ruxolitinib (overcome stage 3), Standard of care.

Is NCT04366232 still recruiting?

NCT04366232 is currently terminated. Last updated 16 December 2020.

Last reviewed 2020-12-16 · How we verify

NCT04366232: JAKINCOV

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation

Terminated Phase 2 Last updated 16 December 2020

What this trial tests

Phase 2 trial testing Anakinra alone (stages 2b/3) in Covid-19 in 2 participants. Terminated before completion.

Timeline

19 August 2020

Primary endpoint
2 October 2020

2 October 2020

Quick facts

Lead sponsor	Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	2
Start date	19 August 2020
Primary completion	2 October 2020
Estimated completion	2 October 2020
Sites	3 locations across France

Drugs / interventions tested

Anakinra alone (stages 2b/3) — full drug profile →
Anakinra and Ruxolitinib (overcome stage 3) — full drug profile →
Standard of care

Conditions studied

Covid-19 — all drugs for Covid-19 →

Sponsor

Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer

Who can join

18 and older, any sex, with Covid-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

During SARS-Cov2 infection with serious respiratory implication and high systemic inflammation level, intravenous ANAKINRA alone or associated with RUXOLITINIB for severe cases might reduce inappropriate systemic inflammatory response, improve breathing and decrease occurrence or duration of ARDS and associated mortality.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts.
Wang J, Jiang M, Chen X, Montaner LJ. · · 2020 · cited 551× · PMID 32534467 · DOI 10.1002/jlb.3covr0520-272r
Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19.
Luo W, Li YX, Jiang LJ, Chen Q, et al · · 2020 · cited 217× · PMID 32580895 · DOI 10.1016/j.tips.2020.06.007
COVID-19 and Cancer: Current Challenges and Perspectives.
Bakouny Z, Hawley JE, Choueiri TK, Peters S, et al · · 2020 · cited 201× · PMID 33049215 · DOI 10.1016/j.ccell.2020.09.018
Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19.
Cauchois R, Koubi M, Delarbre D, Manet C, et al · · 2020 · cited 158× · PMID 32699149 · DOI 10.1073/pnas.2009017117
Viral Respiratory Pathogens and Lung Injury.
Clementi N, Ghosh S, De Santis M, Castelli M, et al · · 2021 · cited 127× · PMID 33789928 · DOI 10.1128/cmr.00103-20
JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy.
Satarker S, Tom AA, Tom AA, Shaji RA, et al · · 2021 · cited 117× · PMID 33245005 · DOI 10.1080/00325481.2020.1855921
Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies.
Market M, Angka L, Martel AB, Bastin D, et al · · 2020 · cited 115× · PMID 32655581 · DOI 10.3389/fimmu.2020.01512
Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies.
Bonaventura A, Vecchié A, Wang TS, Lee E, et al · · 2020 · cited 112× · PMID 32719685 · DOI 10.3389/fimmu.2020.01625

Verify or expand the search:

Other recruiting trials for Covid-19

Currently open trials in the same condition.

NCT05943743 — Hiccups and Obstacles Of E-Learning Among Medical Sudents · recruiting
NCT04466683 — Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia · Phase 2 · active not recruiting
NCT04433364 — COPE - COVID-19 in Pregnancy and Early Childhood · active not recruiting
NCT04568148 — COVID-19 Biorepository · active not recruiting
NCT04360538 — Long Term Outcomes of Patients With COVID-19 · active not recruiting

Other Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer trials

Trials by the same sponsor.

NCT07355582 — Injury Incidence, Severity and Burden in Elite Youth Rugby Players · recruiting
NCT06865053 — Screening for Heart Failure in General Medicine Consultations · completed
NCT06863246 — Postural Control in Chronic Obstructive Pulmonary Disease · completed
NCT06871670 — Force Control in Chronic Obstructive Pulmonary Disease · completed
NCT06857396 — Tracheal Exposure Without Tracheostomy Completion in Trans-oral Robotic Oncologic Surgery · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04366232 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Last refreshed: 16 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04366232.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing